General Therapies
Total Payments
$832,353
Transactions
119
Doctors
0
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2023 | $830,816 | 116 | 0 |
| 2021 | $1,537 | 3 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $830,816 | 116 | 99.8% |
| Grant | $1,537 | 3 | 0.2% |
Payments by Type
Research
$830,816
116 transactions
General
$1,537
3 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| INTERRUPT AF | Boston Scientific Corporation | $246,909 | 0 |
| Time to Revascularization and Outcomes for Patients with Critical Limb Ischemia Establishing the Door to Limb D2L Time | Boston Scientific Corporation | $143,798 | 0 |
| Safety Assessment of Femoropoliteal Endovascular Treatment with Paclitaxel coated Devices SAFE PAD Study | Boston Scientific Corporation | $94,297 | 0 |
| IHTP Phase 2 | Boston Scientific Corporation | $79,725 | 0 |
| Evaluation of the Impact of a Forward Viewing Scope at the Time of ERCP | Boston Scientific Corporation | $58,500 | 0 |
| EUS guided gastroenterostomy versus enteral stenting for palliation of malignant gastric outlet obstruction a randomized clinical trial | Boston Scientific Corporation | $50,000 | 0 |
| RHYTHMIA vs CARTO in redo ablation Procedures for Atrial Fibrillation The MAP AF study | Boston Scientific Corporation | $46,000 | 0 |
| Pre Clinical Comparative Study of MANTIS Clip Versus Other Endoscopic Devices for GI Full Thickness Closure | Boston Scientific Corporation | $45,520 | 0 |
| EBUS MFB for PD L1 | Boston Scientific Corporation | $23,658 | 0 |
| Use of Machine learning for diagnosis of billiary pathology during cholangioscopy | Boston Scientific Corporation | $15,000 | 0 |
| The efficacy of the Smart Pass filter to Reduce the Risk for inappropriate subcutaneous implantable cardioverter defibrillator shocks from myopotential interference | Boston Scientific Corporation | $12,500 | 0 |
| An ex vivo large bowel study to investigate closure of mucosal and colorectal wall defects using the Boston Scientific Mantis clip | Boston Scientific Corporation | $11,920 | 0 |
| HUCS | Boston Scientific Corporation | $2,989 | 0 |
Top Doctors Receiving Payments for General Therapies
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Baltimore, MD | $832,353 | 119 |
Ad
Manufacturing Companies
- Boston Scientific Corporation $830,816
- BOSTON SCIENTIFIC CORPORATION $1,537
Product Information
- Type Device
- Total Payments $832,353
- Total Doctors 0
- Transactions 119
About General Therapies
General Therapies is a device associated with $832,353 in payments to 0 healthcare providers, recorded across 119 transactions in the CMS Open Payments database. The primary manufacturer is BOSTON SCIENTIFIC CORPORATION.
Payment data is available from 2021 to 2023. In 2023, $830,816 was paid across 116 transactions to 0 doctors.
The most common payment nature for General Therapies is "Unspecified" ($830,816, 99.8% of total).
General Therapies is associated with 13 research studies, including "INTERRUPT AF" ($246,909).